Literature DB >> 33865243

Clinical Value of Serum CEA, CA24-2 and CA19-9 in Patients with Colorectal Cancer.

Hui Rao, Heming Wu, Qingyan Huang, Zhikang Yu, Zhixiong Zhong.   

Abstract

BACKGROUND: To investigate the clinical value of serum concentration of carcinoembryonic antigen (CEA), carbohydrate antigen 24-2 (CA24-2), and carbohydrate antigen 19-9 (CA19-9) in the detection of colorectal cancer (CRC).
METHODS: The serum levels of tumor markers and KRAS/NRAS/PIK3CA/BRAF gene mutations were detected in patients with colorectal cancer. Clinical medical records in colorectal cancer patients were collected.
RESULTS: A total of 2,281 patients were recruited in the study, included 1,578 colorectal cancer patients and 703 controls. CEA, CA24-2, and CA19-9 concentrations were significantly higher in the colorectal cancer group than in the control group. The sensitivity of these tumor markers sorted in descending order was CEA>CA19-9>CA24-2. The best specificity was CA24-2, followed by CA19-9 and CEA, with all were more than 92%. The combination of CEA, CA19-9, and CA24-2 ranked the best sensitivity and specificity for colorectal cancer diagnosis. The prediction equation excluding the risk of colorectal cancer was. Probability (normal) = Exp (-5.47 - 0.28*CEA - 0.11*CA242 + 0.001*CA199)/(1+ Exp (-5.47 - 0.28*CEA - 0.11*CA242 + 0.001*CA199)). Besides, there were no significant differences in age, gender, histology type, differentiation, depth of invasion, and TNM stage in KRAS/ NRAS, BRAF, and PIK3CA mutations compared with wild type.
CONCLUSIONS: Serum CEA, CA24-2, and CA19-9 are valuable indicators for predicting the risk of colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33865243     DOI: 10.7754/Clin.Lab.2020.200828

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  4 in total

1.  Salivary Fusobacterium nucleatum serves as a potential biomarker for colorectal cancer.

Authors:  Xin Zhang; Yaping Zhang; Xinru Gui; Yanli Zhang; Zhenhong Zhang; Wendan Chen; Xiaowei Zhang; Yanxiang Wang; Mengjiao Zhang; Ziqi Shang; Yiwei Xin; Yi Zhang
Journal:  iScience       Date:  2022-04-04

2.  HMGB3 is a Potential Therapeutic Target by Affecting the Migration and Proliferation of Colorectal Cancer.

Authors:  Wenjing Gong; Yang Guo; Hang Yuan; Xinye Hu; Rui Chai; Boan Zheng; Ziang Wan; Shiliang Tu
Journal:  Front Cell Dev Biol       Date:  2022-05-31

3.  Optimal Strategy for Colorectal Cancer Patients' Diagnosis Based on Circulating Tumor Cells and Circulating Tumor Endothelial Cells by Subtraction Enrichment and Immunostaining-Fluorescence In Situ Hybridization Combining with CEA and CA19-9.

Authors:  Shimu Luo; Yanghang Ou; Tingjin Zheng; Huihui Jiang; Yibo Wu; Jiangman Zhao; Zhishan Zhang
Journal:  J Oncol       Date:  2021-12-24       Impact factor: 4.375

Review 4.  TCR engineered T cells for solid tumor immunotherapy.

Authors:  Yikai Zhang; Zhipeng Liu; Wei Wei; Yangqiu Li
Journal:  Exp Hematol Oncol       Date:  2022-06-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.